The concept of synthetic lethality, whereby a single gene defect is compatible with cellular survival but simultaneous defects in two genes result in cell death or impaired cellular fitness1,2, is an increasingly explored therapeutic approach to exploiting cancer-specific vulnerabilities. Synthetic lethali...
Treatment with targeted drugs has primarily focused on the genes and pathways that are mutated in cancer, which severely limits the repertoire of drug targets. Synthetic lethality exploits the notion that the presence of a mutation in a cancer gene is often associated with a new vulnerability that...
Although synthetic lethality is not a new idea, recent advances, including CRISPR-based gene editing, have made possible systematic screens for synthetic lethal drug targets in human cancers. Such approaches have broad potential to drive the discovery of the next wave of genetic cancer targets and ...
(2008) Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle 7: pp. 2987-2990Chan DA, Giaccia AJ. Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle. 2008;7:2987-90....
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines.
With the introduction of the first synthetic lethal drug (the PARP inhibitor olaparib in ovarian cancer with BRCA1 mutation), research into synthetic lethality has also become a hotspot. High-throughput screening with CRISPR-Cas9 and shRNA technology has revealed a large number of synthetic lethal ...
While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL candidates found via experimental screens often have limited translational value. Here we present a data-driven approach, ISLE (identification of clinically relevan
Synthetic lethality (SL) has been proposed as a strategy to specifically target cells harboring cancer mutations while leaving unmutated, non-cancer cells ... M Bailey,N O'Neil,D Pel,... - 《Molecular Cancer Therapeutics》 被引量: 0发表: 2013年 加载更多研究点推荐 synthetic lethality cohesin ...
Researchers Investigating a Class of Drugs that Could Short-Circuit Cancer Cells at Molecular Level For the past few years, drugs exploiting synthetic lethality have gained attention as novel anticancer agents. Breast and ovarian cancers with mutated BRCA1 or 2, essential components of a pathway for...
Synthetic lethal strategies for the development of cancer therapeutics Natalie Y. L. Ngoi David Gallo Timothy A. Yap Nature Reviews Clinical Oncology(2025) Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma Feras E. Machour ...